Skyline Dx, Janssen Partner on Adverse Reaction Risk Test for Multiple Myeloma Drug

Skyline will collaborate with Janssen to develop a test to identify patients at increased risk of side effects from a multiple myeloma drug.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.